NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
10 trialsNCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04751929 2026-02-20
Abemaciclib With or Without Atezolizumab for mCRPC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06835972 2026-01-15
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03837821 2025-11-18
CLONEVO
Weill Medical College of Cornell University
Phase EARLY_PHASE1 Active not recruiting
NCT05113537 2025-09-18
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT04627064 2025-07-25
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Phase 1 Completed
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03706365 2025-04-20
CYCLONE 2
Eli Lilly and Company
Phase 2/3 Active not recruiting